188 related articles for article (PubMed ID: 20067604)
1. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
Sutherland RL; Musgrove EA
Breast Cancer Res; 2009; 11(6):112. PubMed ID: 20067604
[TBL] [Abstract][Full Text] [Related]
2. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
3. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
6. Targeting the RB-E2F pathway in breast cancer.
Johnson J; Thijssen B; McDermott U; Garnett M; Wessels LF; Bernards R
Oncogene; 2016 Sep; 35(37):4829-35. PubMed ID: 26923330
[TBL] [Abstract][Full Text] [Related]
7. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
Kumarasamy V; Nambiar R; Wang J; Rosenheck H; Witkiewicz AK; Knudsen ES
Oncogene; 2022 Jul; 41(27):3524-3538. PubMed ID: 35676324
[TBL] [Abstract][Full Text] [Related]
8. CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
Liu W; Zhang R; Yu X; Zhang Y; Kang T; Liao D
Med Oncol; 2023 Aug; 40(9):267. PubMed ID: 37567972
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
[TBL] [Abstract][Full Text] [Related]
10. The Role of CD4/6 Inhibitors in Breast Cancer Treatment.
Purohit L; Jones C; Gonzalez T; Castrellon A; Hussein A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279242
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Riess C; Irmscher N; Salewski I; Strüder D; Classen CF; Große-Thie C; Junghanss C; Maletzki C
Cancer Metastasis Rev; 2021 Mar; 40(1):153-171. PubMed ID: 33161487
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations.
Brastianos PK; Kim AE; Wang N; Lee EQ; Ligibel J; Cohen JV; Chukwueke UN; Mahar M; Oh K; White MD; Shih HA; Forst D; Gainor JF; Heist RS; Gerstner ER; Batchelor TT; Lawrence D; Ryan DP; Iafrate AJ; Giobbie-Hurder A; Santagata S; Carter SL; Cahill DP; Sullivan RJ
Nat Cancer; 2021 May; 2(5):498-502. PubMed ID: 35122016
[TBL] [Abstract][Full Text] [Related]
13. Acute-on-Chronic Liver Failure Incited by Cyclin-Dependent Kinase Inhibitor Therapy for Breast Cancer Effectively Treated With Liver Transplantation.
Kalas V; Nguyen J; Wan AW; Dietch ZC; Kulik L; Hughes DL
ACG Case Rep J; 2024 Jan; 11(1):e01253. PubMed ID: 38274302
[TBL] [Abstract][Full Text] [Related]
14. CDK8: a new breast cancer target.
Crown J
Oncotarget; 2017 Feb; 8(9):14269-14270. PubMed ID: 28209918
[No Abstract] [Full Text] [Related]
15. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer.
Cadoo KA; Gucalp A; Traina TA
Breast Cancer (Dove Med Press); 2014; 6():123-33. PubMed ID: 25177151
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure.
Dean JL; Thangavel C; McClendon AK; Reed CA; Knudsen ES
Oncogene; 2010 Jul; 29(28):4018-32. PubMed ID: 20473330
[TBL] [Abstract][Full Text] [Related]
19. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
20. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
